GSK mRNA flu vaccine candidate shows positive results in trial

Positive results for A and B strains in younger, older adults (Il Sole 24 Ore Radiocor) - London, 12 Sep - UK pharmaceutical company GSK announced positive headline data from its phase II seasonal influenza mRNA vaccine programme with the shot demonstrating positive A and B strain immune responses relative to standard of care in both younger and older adults.

In both younger and older adults, pre-defined success criteria were met. Interim data suggest the vaccine candidates have an acceptable safety and reactogenicity profile for all mRNA formulations tested.

These results build on the previous phase II trial and confirm the mRNA platform elicits strong overall antibody titres with an acceptable safety profile. With these results, the GSK mRNA seasonal influenza vaccine programme will progress into late-stage clinical development.

GSK recently signed a new licensing agreement with CureVac to assume full control of developing and manufacturing influenza and COVID-19 candidate vaccines. GSK said it continues to develop and optimise its mRNA capabilities through investments and partnerships, including in AI/ML-based sequence optimisation, nanoparticle design and manufacturing.

AAA-Sch

(RADIOCOR) 12-09-24 11:22:00 (0244) 5 NNNN